Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
T-lymphoblastic lymphoma (T-LBL) is a rare form of aggressive non-Hodgkin’slymphoma. The standard approach for management of T-LBL involves intensivemultiagent chemotherapy regimens for induction and consolidation phases withcentral nervous system prophylaxis and a maintenance phase lasting 12-18 months. We report on a case of long-term survival after one cycle of hyperfractionatedcyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) andhigh-dose methotrexate. A 30-year-old woman diagnosed with T-LBL with a largemediastinal mass underwent one cycle of hyper-CVAD. Four days after the start oftreatment, the mediastinal mass was markedly reduced. Treatment continued withone cycle of consolidation chemotherapy, comprising high-dose methotrexate andhigh-dose cytarabine. The patient then refused all further chemotherapeutictreatment. Seven years have passed without relapse.
Abstract
T-lymphoblastic lymphoma (T-LBL) is a rare form of aggressive non-Hodgkin’slymphoma. The standard approach for management of T-LBL involves intensivemultiagent chemotherapy regimens for induction and consolidation phases withcentral nervous system prophylaxis and a maintenance phase lasting 12-18 months. We report on a case of long-term survival after one cycle of hyperfractionatedcyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) andhigh-dose methotrexate. A 30-year-old woman diagnosed with T-LBL with a largemediastinal mass underwent one cycle of hyper-CVAD. Four days after the start oftreatment, the mediastinal mass was markedly reduced. Treatment continued withone cycle of consolidation chemotherapy, comprising high-dose methotrexate andhigh-dose cytarabine. The patient then refused all further chemotherapeutictreatment. Seven years have passed without relapse.
참고문헌 (15)
- "A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project", Blood, 89, pp.3909~3918 (1997)
- Portell CA, "Adult lymphoblastic lymphoma", Cancer J, 18, pp.432~438 (2012)
- Sweetenham JW, "Treatment of lymphoblastic lymphoma in adults", Oncology(Williston Park), 23, pp.1015~1020 (2009)
- Hoelzer D, "T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?", Clin Lymphoma Myeloma, 9(Suppl 3), pp.S214~221 (2009)
- Raetz EA, "Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma", Pediatr Blood Cancer, 47, pp.130~140 (2006)
- Uyttebroeck A, "Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy : long term results of the EORTC CLG 58881 trial", Eur J Cancer, 44, pp.840~846 (2008)
- Jabbour E, "High survival rate with the LMT-89 regimen in lymphoblastic lymphoma(LL), but not in T-cell acute lymphoblastic leukemia(T-ALL)", Leukemia, 20, pp.814~819 (2006)
- Cortelazzo S, "Lymphoblastic lymphoma", Crit Rev Oncol Hematol, 79, pp.330~343 (2011)
- Thomas DA, "Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma", Blood, 104, pp.1624~1630 (2004)
- Hoelzer D, "Treatment of lymphoblastic lymphoma in adults", Best Pract Res Clin Haematol, 15, pp.713~728 (2002)
- Bouabdallah R, "Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma : a report on 62 patients from a single center", Ann Oncol, 9, pp.619~625 (1998)
- Ceesay MM, "Spontaneous remission of T lymphoblastic lymphoma", J Clin Pathol, 61, pp.955~957 (2008)
- Reiter A, "Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma : a BFM group report", Blood, 95, pp.416~421 (2000)
- Coleman CN, "Treatment of lymphoblastic lymphoma in adults", J Clin Oncol, 4, pp.1628~1637 (1986)
- Hoelzer D, "Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia", Blood, 99, pp.4379~4385 (2002)